#gilead-sciences

[ follow ]
#lenacapavir
Medicine
fromAdvocate.com
7 months ago

Twice-yearly injectable lenacapavir, an HIV-prevention drug, reduces risk by 96%

Lenacapavir, a twice-yearly injectable, is shown to be more effective than Truvada in preventing HIV in recent clinical trials.
Health
fromwww.mercurynews.com
5 months ago

A twice-yearly shot could help end AIDS. But will it get to everyone who needs it?

Gilead's lenacapavir shows exceptional efficacy in preventing HIV and is a potential game-changer in the global fight against AIDS.
fromwww.nytimes.com
7 months ago
Medicine

Gilead Agrees to Allow Generic Version of Groundbreaking H.I.V. Shot in Poor Countries

Gilead aims to broaden access to lenacapavir through generic production in low-income countries but excludes middle-income nations, highlighting healthcare disparities.
Medicine
fromAdvocate.com
7 months ago

Twice-yearly injectable lenacapavir, an HIV-prevention drug, reduces risk by 96%

Lenacapavir, a twice-yearly injectable, is shown to be more effective than Truvada in preventing HIV in recent clinical trials.
Health
fromwww.mercurynews.com
5 months ago

A twice-yearly shot could help end AIDS. But will it get to everyone who needs it?

Gilead's lenacapavir shows exceptional efficacy in preventing HIV and is a potential game-changer in the global fight against AIDS.
fromwww.nytimes.com
7 months ago
Medicine

Gilead Agrees to Allow Generic Version of Groundbreaking H.I.V. Shot in Poor Countries

Gilead aims to broaden access to lenacapavir through generic production in low-income countries but excludes middle-income nations, highlighting healthcare disparities.
more#lenacapavir
fromSFGATE
5 months ago
Miscellaneous

Biotech giant Gilead lays off 104 from Bay Area HQ, including execs

Gilead Sciences is reducing its workforce amid a strategic reallocation of resources for future product launches.
[ Load more ]